Abstract: Trophoblast cell surface antigen 2 (Trop2) is a glycoprotein that is barely expressed in normal tissues but highly expressed in malignant tumors, and is significantly associated with poor prognosis. Therefore, Trop2 has become a potential therapeutic target for solid tumors. Currently, a variety of targeted therapeutics against Trop2 have been developed, such as anti-Trop2 antibodies and antibody-drug conjugate drugs (ADCs) targeting Trop2. Some drugs have been approved or are in clinical trials for cancer treatment. In this review, we describe the structure of Trop2 gene and its mechanism of action in cancer, and summarize the research on Sacituzumab Govitecan which is an ADC drug targeting Trop2 protein, to provide references for clinical development of more effective and safe Trop2-targeting drugs.